This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tough, D. F. Articles by Chow, D. A. Search for Related Content PubMed PubMed Citation Articles by Tough, D. F. Articles by Chow, D. A.

Tumorigenicity of Murine Lymphomas Selected through Fluorescence-detected Natural Antibody Binding¹

Department of Immunology, University of Manitoba and Manitoba Institute of Cell Biology, Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba, R3E 0V9 Canada

Fluorescence-activated cell sorting was used to isolate high and low IgM natural antibody (NAb) binding populations from a heterogeneous line of the L5178Y-F9 murine lymphoma. The ranking of NAb binding and complement-dependent NAb lysis of the selected and starting lines were the same and opposite to that of their tumorigenicity in syngeneic DBA/2 mice. L5178Y-F9 and SL2-5 clones repeatedly treated with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate and selected by fluorescence-activated cell sorting for high NAb binding exhibited increases in NAb binding and sensitivity to complement-dependent NAb lysis which corresponded with reduced tumor frequencies of threshold inocula. Although the high NAb binding SL2-5 line was slightly more sensitive to natural killer (NK) cell cytolysis, changes in susceptibility to activated macrophages or hypotonic lysis were not consistent with the observed reductions in tumor frequency so that the selected alterations in NAb binding corresponded best with tumorigenicity. These data confirm the same inverse relationship exhibited previously by in vivo and in vitro selected tumor variants and provide more precise evidence supporting a role for NAb in host resistance against tumor foci.

¹ Supported by the Medical Research Council of Canada. Animals were maintained under guidelines set forth by the University of Manitoba.

² Recipient of a Medical Research Council of Canada Studentship.

³ National Cancer Institute of Canada Research Scholar. To whom requests for reprints should be addressed, at Department of Immunology, University of Manitoba and Manitoba Institute of Cell Biology, Manitoba Cancer Treatment and Research Foundation, 100 Olivia Street, Winnipeg, Manitoba, R3E 0V9, Canada.

Received 6/ 8/87. Revised 10/16/87. Accepted 10/19/87.